Agilent Technologies (Agilent Technologies) Debt-to-Equity

: 0.41 (As of Jan. 2024)

View and export this data going back to 1999. Start your Free Trial

Agilent Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0 Mil. Agilent Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $2,555 Mil. Agilent Technologies's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $6,188 Mil. Agilent Technologies's debt to equity for the quarter that ended in Jan. 2024 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Agilent Technologies's Debt-to-Equity or its related term are showing as below:

A' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.31 Med: 0.47 Max: 0.61
Current: 0.41

During the past 13 years, the highest Debt-to-Equity Ratio of Agilent Technologies was 0.61. The lowest was 0.31. And the median was 0.47.

A's Debt-to-Equity is ranked worse than
60.91% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs A: 0.41

Agilent Technologies Debt-to-Equity Historical Data

The historical data trend for Agilent Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

0.51

0.48

0.51

0.52

0.47

Agilent Technologies Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.53	0.47	0.50	0.47	0.41

Competitive Comparison

For the Diagnostics & Research subindustry, Agilent Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agilent Technologies Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Agilent Technologies's Debt-to-Equity falls into.

Agilent Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Agilent Technologies's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2735)	/	5845
	=	0.47

Agilent Technologies's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2555)	/	6188
	=	0.41

Agilent Technologies (NYSE:A) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Agilent Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Agilent Technologies (Agilent Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

A:Mexico 1A:Italy AG8:Germany AG8:Germany

Address

5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051

Website

https://www.agilent.com

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Executives

Philip Binns	officer: Senior Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves	officer: V.P., Corporate Controller	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen	officer: Sr. Vice President	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen	officer: CEO and President	5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten	director	5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand	director	C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj	director	C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson	director	VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh	director	C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop	director	60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky	director	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell	officer: Senior Vice President	5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051